Terazosin hydrochloride

SKU: orb1310845

Description

Terazosin hydrochloride is a selective α1-adrenergic antagonist used in research to study smooth muscle relaxation in the bladder neck and vasculature. It is applied in models of benign prostatic hyperplasia (BPH) and hypertension, facilitating both in vitro receptor binding assays and in vivo pharmacological studies.

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 63074-08-8
• MW: 423.89
• Purity: >99.99% (May vary between batches)
• Formula: C₁₉H₂₆ClN₅O₄
• SMILES: COC1=C(OC)C=C2C(C(N)=NC(N3CCN(C(C4CCCO4)=O)CC3)=N2)=C1.Cl
• Target: Adrenergic Receptor
• Solubility: DMSO:45 mg/mL (106.16 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble);H2O:1 mg/mL (2.36 mM)

Bioactivity

• In Vivo:
  Terazosin produces a dose-dependent, complete inhibition of motor activity and catalepsy. Intraventricularly administered this antagonist protects striatal and cerebral cortical alpha 1 receptors but not striatal or cortical D1 receptors from in vivo alkylation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroxyquinoline. Intraventricular terazosin also produces hypothermia and a reduced respiratory rate suggestive of a reduced sympathetic outflow. Terazosin does not impair performance on a horizontal wire test or the ability to make co-ordinated movements in a swim test.Terazosin significantly inhibits vascular endothelial growth factor induced angiogenesis in nude mice with an IC50 of 7.9 μM, showing that it has a more potent anti-angiogenic than cytotoxic effect.
• In Vitro:
  Terazosin induces cytotoxicity in PC-3 and human benign prostatic cells with an IC50 of more than 100 μM. Terazosin also effectively inhibited vascular endothelial growth factor induced proliferation and tube formation in cultured human umbilical vein endothelial cells (IC50 9.9 and 6.8 μM, respectively).
• Cell Research:
  To determine the cytotoxic effect mode of action, several identification techniques were used in the current study. Apoptotic cells are detected in situ using terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling. Results show a positive reaction after a 12-hour treatment of PC-3 cells with terazosin (100 μM). (Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Zayasel, prostatic, Terazosin HCl, Terazosin, Terazosin hydrochloride, Terazosine, Terazosin Hydrochloride, quinazoline, pressure, α-adrenergic receptor, α1-adrenoceptor, Adrenergic Receptor, AdrenergicReceptor, bladder, blood, Blavin, benign, Beta Receptor, Fosfomic, Inhibitor, Hytrin, hyperplasia, high, inhibit

Compound Identifiers

PubChem CID

44383